Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.